DK3319601T3 - Fremgangsmåde til behandling af hepatisk encefalopati - Google Patents

Fremgangsmåde til behandling af hepatisk encefalopati Download PDF

Info

Publication number
DK3319601T3
DK3319601T3 DK17742782T DK17742782T DK3319601T3 DK 3319601 T3 DK3319601 T3 DK 3319601T3 DK 17742782 T DK17742782 T DK 17742782T DK 17742782 T DK17742782 T DK 17742782T DK 3319601 T3 DK3319601 T3 DK 3319601T3
Authority
DK
Denmark
Prior art keywords
hepatic encephalopathy
treating hepatic
treating
encephalopathy
hepatic
Prior art date
Application number
DK17742782T
Other languages
English (en)
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Application granted granted Critical
Publication of DK3319601T3 publication Critical patent/DK3319601T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17742782T 2016-07-29 2017-07-28 Fremgangsmåde til behandling af hepatisk encefalopati DK3319601T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
DK3319601T3 true DK3319601T3 (da) 2019-11-18

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17742782T DK3319601T3 (da) 2016-07-29 2017-07-28 Fremgangsmåde til behandling af hepatisk encefalopati

Country Status (23)

Country Link
US (2) US10117854B2 (da)
EP (2) EP3275439A1 (da)
JP (1) JP2019522030A (da)
KR (1) KR20190034550A (da)
AU (1) AU2017303346A1 (da)
BR (1) BR112019001178A2 (da)
CA (1) CA3031302A1 (da)
CY (1) CY1122348T1 (da)
DK (1) DK3319601T3 (da)
EA (1) EA201990413A1 (da)
ES (1) ES2751154T3 (da)
HK (1) HK1254833B (da)
HR (1) HRP20191798T1 (da)
HU (1) HUE046590T2 (da)
IL (1) IL264460B (da)
LT (1) LT3319601T (da)
MA (1) MA42419B1 (da)
ME (1) ME03520B (da)
PL (1) PL3319601T3 (da)
PT (1) PT3319601T (da)
RS (1) RS59300B1 (da)
SI (1) SI3319601T1 (da)
WO (1) WO2018020010A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX2018004788A (es) * 2018-04-18 2019-10-21 Alparis Sa De Cv Nuevas fases solidas de rifaximina.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
HRP20191798T1 (hr) 2019-12-27
PT3319601T (pt) 2019-09-18
IL264460B (en) 2021-06-30
EP3275439A1 (en) 2018-01-31
IL264460A (en) 2019-02-28
US20190070150A1 (en) 2019-03-07
JP2019522030A (ja) 2019-08-08
ES2751154T3 (es) 2020-03-30
SI3319601T1 (sl) 2019-11-29
RS59300B1 (sr) 2019-10-31
AU2017303346A1 (en) 2019-01-31
EP3319601B1 (en) 2019-08-28
WO2018020010A1 (en) 2018-02-01
PL3319601T3 (pl) 2020-06-29
EP3319601A1 (en) 2018-05-16
MA42419B1 (fr) 2019-11-29
US10328059B2 (en) 2019-06-25
US10117854B2 (en) 2018-11-06
CA3031302A1 (en) 2018-02-01
HUE046590T2 (hu) 2020-03-30
HK1254833B (zh) 2020-05-22
KR20190034550A (ko) 2019-04-02
ME03520B (me) 2020-04-20
US20180214417A1 (en) 2018-08-02
EA201990413A1 (ru) 2019-06-28
MA42419A (fr) 2018-05-16
BR112019001178A2 (pt) 2019-04-30
LT3319601T (lt) 2019-11-11
CY1122348T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
DK3315610T3 (da) Fremgangsmåde til fremstilling af fucosylerede oligosaccharider
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3241026T3 (da) Fremgangsmåde til absolut kvantificering af naturligt forarbejdede hla-begrænsede cancerpeptider
DK3366295T3 (da) Fremgangsmåder til behandling af filoviridae virusinfektioner
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3402773T3 (da) Fremgangsmåde til fremstilling af methanol
DK3261726T3 (da) Sammensætning til behandling af acne
DK3515990T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3349772T3 (da) Fremgangsmåde til fremstilling af urteekstrakter
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK3506904T3 (da) Behandling af demens
DK3307267T3 (da) Behandling af multipel sklerose
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3346990T3 (da) Fremgangsmåde til stråleformaling
DK3511418T3 (da) Fremgangsmåde til nedbrydning af mannanholdige celluloseholdige materialer
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3363148T3 (da) Afdækning af krypteringsanvendelse
DK2921050T3 (da) Fremgangsmåde til udbringning af plantebeskyttelsesmidler
DK3156539T3 (da) Kontinuerlig fremgangsmåde til forbehandling af et ligno-celluloseholdigt råmateriale